SCHEMBL4173576

SCHEMBL4173576

N=C(N)Nc1cccc(S(=O)(=O)NCc2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.61
KEAP1 Q14145 1/20 0.56
HDAC2 Q92769 2/20 0.54
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
HTT P42858 1/20 0.54
ALDH1A1 P00352 2/20 0.52
PKM P14618 2/20 0.52
HDAC3 O15379 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC10 Q969S8 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
HDAC9 Q9UKV0 1/20 0.52
HDAC5 Q9UQL6 1/20 0.52
CYP19A1 P11511 2/20 0.51
LMNA P02545 5/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19639277 0.85 KEAP1 (0.61) NAMPTKEAP1HTTALDH1A1LMNA
SCHEMBL4168948 0.85 KEAP1 (0.61) NAMPTKEAP1HTTALDH1A1LMNA
SCHEMBL6285904 0.85 NAMPT (0.56) NAMPTHDAC2HDAC8HDAC6HTT
SCHEMBL4159966 0.82 LMNA (0.49) HTTALDH1A1LMNAMAPTCA12
SCHEMBL4162355 0.81 CYP2C19 (0.55) NAMPTALDH1A1PKMMAPTPRMT1
Trifluoroacetic Acid SCHEMBL17894431 0.78 TMPRSS6 (0.54) NAMPTKEAP1HTTALDH1A1LMNA
SCHEMBL4151992 0.77 LMNA (0.52) LMNARAB9ASMN1; SMN2MAPTCA12
SCHEMBL4165927 0.77 ALDH1A1 (0.50) HTTALDH1A1PKMLMNARAB9A
SCHEMBL5032437 0.77 HDAC2 (0.73) KEAP1HDAC2HDAC8HDAC6HTT
SCHEMBL6280117 0.77 MEN1 (0.60) NAMPTSMN1; SMN2MAPTPRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 NAMPT 724/4885KEAP1 3107/4885HDAC2 2273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.